Panacea Biotec has signed agreement with Technology Development Board (TDB), Govt. of India for providing the financial assistance of Rs 28.99 crore for the Development and commercialization of Dengue Tetravalent Vaccine (Live Attenuated, Recombinant, Lyophilized).
Moreover, the company’s collaboration with National Institutes of Health (NIH), USA has led to the development of an advanced Dengue Vaccine in India with proven safety in pre-clinical studies. According to the results from clinical trials conducted by NIH, the candidate Dengue vaccine has been found to stimulate a strong immune response against all 4 serotypes in all age-groups and expected to be a single dose vaccine. Panacea Biotec has obtained Phase I/II clinical trial permission from Drug Controller General of India, New Delhi. Clinical trial lots production is in advanced stages at Panacea Biotec’s cGMP facility and clinical trials will be started by early 2018.
Currently some of the vaccine candidates under development elsewhere require 2-3 doses to achieve desired immune response, while the published clinical data of only licensed vaccine outside India has shown a poor immune response against Type-2 strain of Dengue besides being a 3 dose vaccine and protects only the age group of 9-45 yrs.
Panacea Biotec is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India.
